<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329029</url>
  </required_header>
  <id_info>
    <org_study_id>RO-2455-404-RD</org_study_id>
    <secondary_id>2010-019685-87</secondary_id>
    <secondary_id>U1111-1141-7422</secondary_id>
    <nct_id>NCT01329029</nct_id>
  </id_info>
  <brief_title>Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)</brief_title>
  <acronym>REACT</acronym>
  <official_title>Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 µg Versus Placebo. The REACT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets
      once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who
      are concomitantly treated with a fixed combination of long-acting β2-agonists (LABA) and
      inhaled glucocorticosteroids (ICS). In addition, data on safety and tolerability of
      roflumilast will be obtained. An additional objective is to further characterize the
      population pharmacokinetic profile of roflumilast and roflumilast N oxide and to further
      characterize their pharmacokinetics/pharmacodynamics (PK/PD) relationship in terms of
      efficacy and relevant safety aspects.

      Patients to be included are required to have severe COPD associated with chronic bronchitis
      and a history of frequent exacerbations and must be concomitantly treated with a fixed
      combination of LABA and ICS. Two parallel treatment arms (roflumilast 500 μg once daily and
      placebo) are included.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug tested in this study is called Roflumilast. Roflumilast is being developed to treat
      people who have chronic obstructive pulmonary disease (COPD). This study investigated the
      effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate,
      pulmonary function, and major adverse cardiovascular events (MACE) in COPD patients who were
      concomitantly treated with a fixed combination of long-acting beta-agonists (LABA) and
      inhaled glucocorticosteroids.

      The study was targeted to enroll approximately 1934 patients. Participants were randomly
      assigned (by chance, like flipping a coin) to one of the two treatment groups—which remained
      undisclosed to the patient and study doctor during the study (unless there was an urgent
      medical need):

        -  Roflumilast 500 μg once daily

        -  Placebo (dummy inactive pill) - this was a tablet that looked like the study drug but
           had no active ingredient

      Trial treatment was taken in the morning by mouth after breakfast with some water.

      The trial consisted of the following periods:

        -  Single-blind baseline period (4 weeks) during which all patients received placebo.

        -  Double-blind treatment period (52 weeks) during which patients received either
           roflumilast or matching placebo.

        -  Safety follow-up (30 days after end of treatment (Vend) or premature discontinuation
           date) in case of ongoing Adverse Events at Vend, if necessary.

        -  Follow-up visit 12 weeks after end of treatment, at Week 64 (VFU), only for patients who
           completed the trial as scheduled.

      This multi-center trial was conducted worldwide. The overall time to participate in this
      study was up to 64 weeks. Participants made multiple visits to the clinic which included a
      follow-up visit at week 64.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year</measure>
    <time_frame>52 weeks</time_frame>
    <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First Second (FEV1)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Pulmonary function testing was performed using centralised spirometry. FEV1 is the maximum amount of air that can be forcefully exhaled in one second. Least-squares means is from Analysis of Covariance (ANCOVA) including treatment by time interaction. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Severe COPD Exacerbations Per Patient Per Year</measure>
    <time_frame>52 weeks</time_frame>
    <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. Severe COPD exacerbations were categorized as requiring hospitalization and/or leading to death. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of COPD Exacerbations Per Patient Per Year All Categories</measure>
    <time_frame>52 weeks</time_frame>
    <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing at Least 1 COPD Exacerbation</measure>
    <time_frame>52 weeks</time_frame>
    <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First COPD Exacerbation All Categories</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Time to event was calculated as date of onset of event — date of first intake of double-blind study drug + 1 day for all events: mild, moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Second Moderate or Severe COPD Exacerbation</measure>
    <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
    <description>Time to event was calculated as date of onset of event — date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Third Moderate or Severe COPD Exacerbation</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Time to event was calculated as date of onset of event — date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Needed to Treat to Avoid 1 Moderate or Severe COPD Exacerbation Derived From Exacerbation Per Patient Per Year</measure>
    <time_frame>52 Weeks</time_frame>
    <description>The number needed to treat (NNT) analysis is a simple, concise method to quantify directly the benefits that alternative treatment options have on disease outcomes in terms of the number of patients who need to be treated before a benefit is observed. Risk reduction: Rate(Placebo)— Rate (Roflumilast 500 μg), Number needed to treat for benefit (NNTB): 1/(Risk reduction). A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Moderate or Severe COPD Exacerbation Days</measure>
    <time_frame>52 Weeks</time_frame>
    <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. The number of exacerbation days per patient is the sum of durations (stop date of exacerbation — start date of exacerbation + 1) of all exacerbations within the category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Moderate or Severe COPD Exacerbations Per Participant</measure>
    <time_frame>52 Weeks</time_frame>
    <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Post-Bronchodilator Forced Vital Capacity (FVC)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Post-Bronchodilator Forced Expiratory Flow at 25% to 75% of Vital Capacity (FEF25-75%)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First 6 Seconds (FEV6)</measure>
    <time_frame>52 weeks</time_frame>
    <description>FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first six seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Post-Bronchodilator FEV1/FVC</measure>
    <time_frame>52 weeks</time_frame>
    <description>The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Use of Rescue Medication From Daily Diary</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Salbutamol metered dose inhaler was available as rescue medication during the study. The participant recorded the use of rescue medication in a daily diary. A negative change from Baseline indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in COPD Symptom Score From Daily Diary</measure>
    <time_frame>52 weeks</time_frame>
    <description>Participants recorded COPD symptoms cough and sputum production in a daily diary. Cough was assessed using a 4-point scale where 0=No cough to 3=severe cough and sputum was assessed using a 4-point scale where 0=no sputum production to 3=severe sputum production. Least-squares means from ANCOVA including treatment by time interaction. A negative change from Baseline indicates improvement. Total symptom score is the sum of cough and sputum scores, ranging from 0 (best possible outcome) to 6 (worst possible outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Symptom-Free Days</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Symptoms of COPD (cough, sputum) were recorded in a daily diary. The percentage of days without symptoms is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Rescue Medication-Free Days</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Participants recorded their use of rescue medication in a daily diary. The percentage of days without rescue medication use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in COPD Assessment Test (CAT) Total Score</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Participants completed the CAT questionnaire at Baseline and after 52 Weeks of Treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. A negative change from Baseline indicates improvement. Least-squares means from ANCOVA including treatment by time interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement in CAT</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Participants completed the CAT questionnaire at Baseline and after 52 Weeks of treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. Improvement was defined as a CAT Total Score reduction from Baseline &gt; 1.6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Mortality Due to Any Reason During the Treatment Period Score</measure>
    <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
    <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Mortality Due to COPD Exacerbation During the Treatment Period</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Withdrawal During the Treatment Period</measure>
    <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
    <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Withdrawal Due to COPD Exacerbation During the Treatment Period</measure>
    <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
    <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Major Adverse Cardiovascular Event (MACE) During the Treatment Period</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Composite MACE is a combined endpoint (cardiovascular death [including death due to undetermined cause], nonfatal myocardial infarction, and nonfatal stroke).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Major Adverse Cardiovascular Event (MACE) During the Treatment Period</measure>
    <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
    <description>Composite MACE is a combined endpoint(cardiovascular death [including death due to undetermined cause], nonfatal myocardial infarction, and nonfatal stroke). Time to event was calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participant With All-Cause Hospitalisation During the Treatment Period</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Percentage of patients with at least one hospital admission due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Hospitalisation Due to Any Cause During the Treatment Period</measure>
    <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
    <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Trial Withdrawal Due to an Adverse Event</measure>
    <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
    <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced at Least 1 Treatment Emergent Adverse Event (TEAE)</measure>
    <time_frame>52 Weeks</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Least Square Means was from an ANCOVA model including Last Observation Carried Forward (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Mass Index (BMI)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Body mass index (BMI) is a measure of body fat based on height and weight. Least Square Means was from an ANCOVA model including LOCF.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1945</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>500 µg, once daily</description>
    <arm_group_label>Roflumilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Giving written informed consent

          -  History of COPD (according to GOLD 2009) for at least 12 months prior to baseline
             Visit V0 associated with chronic productive cough for 3 months in each of the 2 years
             prior to baseline visit (with other causes of productive cough excluded)

          -  Age ≥ 40 years

          -  Forced expiratory volume after one second (FEV1)/forced vital capacity (FVC) ratio
             (post-bronchodilator) &lt; 70%

          -  FEV1 (post-bronchodilator) ≤ 50% of predicted

          -  At least two documented moderate or severe COPD exacerbations within one year prior to
             baseline visit

          -  Patients must be pre-treated with LABA and ICS for at least 12 months before baseline
             Visit V0. Up to 3 months before baseline Visit V0 free or fixed combinations of LABA
             and ICS are allowed, including changes in dose, active substances, and brands. In the
             last 3 months before baseline Visit V0 patients must be pre-treated with fixed
             combinations of LABA and ICS at a constant dose (maximum approved dosage strength of
             the combination).

          -  Former smoker (defined as smoking cessation at least one year ago) or current smoker
             both with a smoking history of at least 20 pack years

        Main Exclusion Criteria:

          -  Exacerbations not resolved at first baseline visit

          -  Diagnosis of asthma and/or other relevant lung disease

          -  Known alpha-1-antitrypsin deficiency

          -  Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Concord</city>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational site</name>
      <address>
        <city>Daws Park</city>
        <zip>5041</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Frankston</city>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Toorak Gardens</city>
        <zip>5065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Feldbach</city>
        <zip>8330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Halen</city>
        <zip>3545</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Malmedy</city>
        <zip>4960</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Botucatu</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Florianópolis</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Sao Paolo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Vitória</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Kingston</city>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Lachine</city>
        <zip>H8S 2E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Niagara Falls</city>
        <zip>L2G 1J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Richmond Hill</city>
        <zip>L4C 2N9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Toronto</city>
        <zip>M5T 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Toronto</city>
        <zip>M6H 3M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Winnepeg</city>
        <zip>R2K 3S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>København NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Férolles Attilly</city>
        <zip>77150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Nîmes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Saint-Laurent du Var</city>
        <zip>06700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Fürth</city>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Hannover</city>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Rüdersdorf</city>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Alexandroupolis</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Heraklion, Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Kavala</city>
        <zip>65201</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Larissa</city>
        <zip>41100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Marousi</city>
        <zip>15126</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Cegléd</city>
        <zip>2700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Csorna</city>
        <zip>9300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Erd</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Pécs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Siófok</city>
        <zip>8600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Sopron</city>
        <zip>9400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Törökbálint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Jerusalm</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>67891</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <zip>44011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Cheongju</city>
        <zip>361-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Wonju</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>'s Hertogenbosch</city>
        <zip>5200 ME</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Amersfoort</city>
        <zip>3800 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Enschede</city>
        <zip>7500 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-681</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-753</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>91-849</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>94-010</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Olesnica</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Ostrow Wielkopolski</city>
        <zip>63-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-127</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-301</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Zawadzkie</city>
        <zip>47-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117485</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117574</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>125206</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Vsevolozhsk</city>
        <zip>188640</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Bardejov</city>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>821 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Martin</city>
        <zip>036 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Nitra</city>
        <zip>950 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Nove Zamky</city>
        <zip>940 34</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Spisska Nova Ves</city>
        <zip>052 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Auckland Park, Johannesburg Gauteng</city>
        <zip>2006</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Benoni Gauteng</city>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Bloemfontein Free State</city>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Cape Town Western Cape</city>
        <zip>7764</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Durban Kwazulu-Natal</city>
        <zip>4092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Morningside, Johannesburg Gauteng</city>
        <zip>2057</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Thabazimbi Limpopo</city>
        <zip>0380</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Umkomaas Kwazulu-Natal</city>
        <zip>4170</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Witbank Mpumalanga</city>
        <zip>1035</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Terrassa</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Canakkale</city>
        <zip>17020</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Konya</city>
        <zip>42075</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Mersin</city>
        <zip>33079</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>London</city>
        <zip>E2 9JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>April 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2011</study_first_posted>
  <results_first_submitted>March 10, 2015</results_first_submitted>
  <results_first_submitted_qc>September 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 29, 2015</results_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Roflumilast</keyword>
  <keyword>Daxas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 203 investigative sites in Australia, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Korea (Republic of), Netherlands, Poland, Russia, Slovak Republic, South Africa, Spain, Turkey and United Kingdom from 28 May 2011 to 27 May 2014.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) entered a 4 week baseline period during which all patients received placebo then were enrolled equally in 1 of 2 treatment groups, once a day placebo or roflumilast 500 µg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Roflumilast 500 µg</title>
          <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="973"/>
                <participants group_id="P2" count="972"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="969"/>
                <participants group_id="P2" count="966"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="968"/>
                <participants group_id="P2" count="967"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="704"/>
                <participants group_id="P2" count="780"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="269"/>
                <participants group_id="P2" count="192"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>COPD Exacerbation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Pre-defined Discontinuation Criteria</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS) includes all randomised participants who took at least 1 dose of investigational medicinal product (IMP) after randomisation.</population>
      <group_list>
        <group group_id="B1">
          <title>Roflumilast 500 µg</title>
          <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="969"/>
            <count group_id="B2" value="966"/>
            <count group_id="B3" value="1935"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="8.38"/>
                    <measurement group_id="B2" value="64.7" spread="8.37"/>
                    <measurement group_id="B3" value="64.7" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≤ 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="527"/>
                    <measurement group_id="B2" value="542"/>
                    <measurement group_id="B3" value="1069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="442"/>
                    <measurement group_id="B2" value="424"/>
                    <measurement group_id="B3" value="866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="241"/>
                    <measurement group_id="B3" value="492"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="718"/>
                    <measurement group_id="B2" value="725"/>
                    <measurement group_id="B3" value="1443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="940"/>
                    <measurement group_id="B2" value="943"/>
                    <measurement group_id="B3" value="1883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic Of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.20" spread="8.652"/>
                    <measurement group_id="B2" value="168.33" spread="8.198"/>
                    <measurement group_id="B3" value="168.26" spread="8.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.07" spread="17.275"/>
                    <measurement group_id="B2" value="75.60" spread="17.238"/>
                    <measurement group_id="B3" value="75.33" spread="17.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.45" spread="5.474"/>
                    <measurement group_id="B2" value="26.58" spread="5.359"/>
                    <measurement group_id="B3" value="26.52" spread="5.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease (COPD) Severity</title>
          <description>COPD severity was classified according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guideline (2009) as: - Very severe COPD: baseline post-bronchodilator FEV1 %predicted &lt; 30% - Severe COPD: baseline post-bronchodilator FEV1 %predicted ≥ 30% to &lt; 50% - Moderate COPD: baseline post-bronchodilator FEV1 %predicted ≥ 50% to &lt; 80% - Mild COPD: baseline post-bronchodilator FEV1 %predicted ≥ 80%.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="658"/>
                    <measurement group_id="B2" value="677"/>
                    <measurement group_id="B3" value="1335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>COPD Disease Characteristics</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Pure emphysema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Predominantly chronic bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="338"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combined emphysema and chronic bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="626"/>
                    <measurement group_id="B2" value="634"/>
                    <measurement group_id="B3" value="1260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Global Initiative for Chronic Obstructive Lung Disease (GOLD) Patient Group</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>A : low risk, less symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: low risk, more symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C: high risk, less symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D: high risk, more symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="905"/>
                    <measurement group_id="B2" value="907"/>
                    <measurement group_id="B3" value="1812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="411"/>
                    <measurement group_id="B2" value="432"/>
                    <measurement group_id="B3" value="843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="558"/>
                    <measurement group_id="B2" value="534"/>
                    <measurement group_id="B3" value="1092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonsmoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarette Pack Years</title>
          <description>Pack Years = (packs smoked per day) * (years as a smoker)</description>
          <units>pack years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.6" spread="24.55"/>
                    <measurement group_id="B2" value="47.6" spread="23.56"/>
                    <measurement group_id="B3" value="47.6" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-bronchodilator Forced Expiratory Volume in the First Second (FEV1)</title>
          <description>Number of participants for whom pre-bronchodilator FEV1 data was available was 938 and 937 in each treatment arm, respectively.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.999" spread="0.3149"/>
                    <measurement group_id="B2" value="1.016" spread="0.3209"/>
                    <measurement group_id="B3" value="1.008" spread="0.3180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post-bronchodilator FEV1</title>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.066" spread="0.3317"/>
                    <measurement group_id="B2" value="1.078" spread="0.3244"/>
                    <measurement group_id="B3" value="1.072" spread="0.3280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-bronchodilator FEV1 Predicted</title>
          <description>Number of participants for whom pre-bronchodilator FEV1 data was available was 938 and 933 in each treatment arm, respectively.</description>
          <units>percent of predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.259" spread="9.0781"/>
                    <measurement group_id="B2" value="33.562" spread="9.0043"/>
                    <measurement group_id="B3" value="33.411" spread="9.0402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post-bronchodilator FEV1 Predicted</title>
          <units>percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.392" spread="9.2484"/>
                    <measurement group_id="B2" value="35.532" spread="8.7573"/>
                    <measurement group_id="B3" value="35.462" spread="9.0045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 Reversibility % Increase</title>
          <description>FEV reversibility (%) = (post-bronchodilator FEV minus pre-bronchodilator FEV) / pre-bronchodilator FEV * 100. Number of participants for whom FEV1 reversibility % increase data was available was 912 and 915 in each treatment arm, respectively.</description>
          <units>percent reversibility</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.465" spread="11.2559"/>
                    <measurement group_id="B2" value="7.383" spread="12.0752"/>
                    <measurement group_id="B3" value="7.424" spread="11.6703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 Reversibility Increase</title>
          <description>Number of participants for whom FEV1 reversibility increase data was available was 912 and 915 in each treatment arm, respectively.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="108.72"/>
                    <measurement group_id="B2" value="65.4" spread="121.55"/>
                    <measurement group_id="B3" value="65.3" spread="115.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post-bronchodilator FEV1/Forced Vital Capacity (FVC)</title>
          <description>Calculated as FEV1/FVC * 100</description>
          <units>FEV1/FVC percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.2" spread="10.81"/>
                    <measurement group_id="B2" value="40.1" spread="10.26"/>
                    <measurement group_id="B3" value="40.1" spread="10.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year</title>
        <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.</description>
        <time_frame>52 weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year</title>
          <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>exacerbations per patient per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.805" lower_limit="0.724" upper_limit="0.895"/>
                    <measurement group_id="O2" value="0.927" lower_limit="0.843" upper_limit="1.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0529</p_value>
            <p_value_desc>Level of significance: 5% 2-sided</p_value_desc>
            <method>Generalized Linear Regression</method>
            <method_desc>Poisson regression model (estimates of exacerbation rates using time in trial as model offset).</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.868</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0633</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.753</ci_lower_limit>
            <ci_upper_limit>1.002</ci_upper_limit>
            <estimate_desc>A rate ratio of &lt; 1 represents a favourable outcome for the test treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First Second (FEV1)</title>
        <description>Pulmonary function testing was performed using centralised spirometry. FEV1 is the maximum amount of air that can be forcefully exhaled in one second. Least-squares means is from Analysis of Covariance (ANCOVA) including treatment by time interaction. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First Second (FEV1)</title>
          <description>Pulmonary function testing was performed using centralised spirometry. FEV1 is the maximum amount of air that can be forcefully exhaled in one second. Least-squares means is from Analysis of Covariance (ANCOVA) including treatment by time interaction. A positive change from Baseline indicates improvement.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="928"/>
                <count group_id="O2" value="941"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.052" spread="0.0064"/>
                    <measurement group_id="O2" value="-0.004" spread="0.0062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of Covariance (ANCOVA) including treatment by time interaction.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>0.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0089</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.038</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Severe COPD Exacerbations Per Patient Per Year</title>
        <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. Severe COPD exacerbations were categorized as requiring hospitalization and/or leading to death. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.</description>
        <time_frame>52 weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Severe COPD Exacerbations Per Patient Per Year</title>
          <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. Severe COPD exacerbations were categorized as requiring hospitalization and/or leading to death. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>exacerbations per patient per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.239" lower_limit="0.201" upper_limit="0.283"/>
                    <measurement group_id="O2" value="0.315" lower_limit="0.270" upper_limit="0.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0175</p_value>
            <method>Generalized Linear Regression</method>
            <method_desc>Analyzed using a negative binomial regression model excluding a correction for overdispersion.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.757</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0889</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.601</ci_lower_limit>
            <ci_upper_limit>0.952</ci_upper_limit>
            <estimate_desc>A rate ratio of &lt; 1 represents a favourable outcome for the test treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of COPD Exacerbations Per Patient Per Year All Categories</title>
        <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.</description>
        <time_frame>52 weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of COPD Exacerbations Per Patient Per Year All Categories</title>
          <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>exacerbations per patient per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.574" lower_limit="0.508" upper_limit="0.648"/>
                    <measurement group_id="O2" value="0.627" lower_limit="0.561" upper_limit="0.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild, Moderate or Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.078" lower_limit="2.723" upper_limit="3.479"/>
                    <measurement group_id="O2" value="3.879" lower_limit="3.492" upper_limit="4.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leading to Hospitalisation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.238" lower_limit="0.200" upper_limit="0.283"/>
                    <measurement group_id="O2" value="0.313" lower_limit="0.268" upper_limit="0.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucocorticosteroids and/or Antibiotics treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.794" lower_limit="0.716" upper_limit="0.88"/>
                    <measurement group_id="O2" value="0.929" lower_limit="0.847" upper_limit="1.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate or Severe and/or treated with Antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.012" lower_limit="0.922" upper_limit="1.110"/>
                    <measurement group_id="O2" value="1.210" lower_limit="1.115" upper_limit="1.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate COPD Exacerbations</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2875</p_value>
            <p_value_desc>Level of significance: 5% 2-sided</p_value_desc>
            <method>Generalized Linear Regression</method>
            <method_desc>Poisson regression model (estimates of exacerbation rates using time in trial as model offset).</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.914</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0771</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.775</ci_lower_limit>
            <ci_upper_limit>1.078</ci_upper_limit>
            <estimate_desc>A rate ratio of &lt; 1 represents a favourable outcome for the test treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mild, Moderate or Severe COPD Exacerbations</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0050</p_value>
            <p_value_desc>Level of significance: 5% 2-sided</p_value_desc>
            <method>Generalized Linear Regression</method>
            <method_desc>Poisson regression model (estimates of exacerbation rates using time in trial as model offset).</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.794</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0654</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.675</ci_lower_limit>
            <ci_upper_limit>0.933</ci_upper_limit>
            <estimate_desc>A rate ratio of &lt; 1 represents a favourable outcome for the test treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>COPD Exacerbations treated with Glucocorticosteroids and/or Antibiotics</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0262</p_value>
            <p_value_desc>Level of significance: 5% 2-sided</p_value_desc>
            <method>Generalized Linear Regression</method>
            <method_desc>Poisson regression model (estimates of exacerbation rates using time in trial as model offset).</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.854</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0605</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.744</ci_lower_limit>
            <ci_upper_limit>0.982</ci_upper_limit>
            <estimate_desc>A rate ratio of &lt; 1 represents a favourable outcome for the test treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate or Severe COPD Exacerbations and/or treated with Antibiotics</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0047</p_value>
            <p_value_desc>Level of significance: 5% 2-sided</p_value_desc>
            <method>Generalized Linear Regression</method>
            <method_desc>Poisson regression model (estimates of exacerbation rates using time in trial as model offset).</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.837</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0528</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.739</ci_lower_limit>
            <ci_upper_limit>0.947</ci_upper_limit>
            <estimate_desc>A rate ratio of &lt; 1 represents a favourable outcome for the test treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Leading to Hospitalisation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0209</p_value>
            <p_value_desc>Level of significance: 5% 2-sided.</p_value_desc>
            <method>Generalized Linear Regression</method>
            <method_desc>Negative binomial regression model (estimates of exacerbation rates)</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.761</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0899</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.604</ci_lower_limit>
            <ci_upper_limit>0.960</ci_upper_limit>
            <estimate_desc>A rate ratio of &lt; 1 represents a favourable outcome for the test treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing at Least 1 COPD Exacerbation</title>
        <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.</description>
        <time_frame>52 weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing at Least 1 COPD Exacerbation</title>
          <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2"/>
                    <measurement group_id="O2" value="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First COPD Exacerbation All Categories</title>
        <description>Time to event was calculated as date of onset of event — date of first intake of double-blind study drug + 1 day for all events: mild, moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.</description>
        <time_frame>52 Weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First COPD Exacerbation All Categories</title>
          <description>Time to event was calculated as date of onset of event — date of first intake of double-blind study drug + 1 day for all events: mild, moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.0" lower_limit="189.0" upper_limit="259.0"/>
                    <measurement group_id="O2" value="180.0" lower_limit="147.0" upper_limit="200.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1461</p_value>
            <p_value_desc>Level of significance: 5% 2-sided.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.917</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0549</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.815</ci_lower_limit>
            <ci_upper_limit>1.031</ci_upper_limit>
            <estimate_desc>A hazards ratio of &lt; 1 represents a lower hazard for the test treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Second Moderate or Severe COPD Exacerbation</title>
        <description>Time to event was calculated as date of onset of event — date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.</description>
        <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Second Moderate or Severe COPD Exacerbation</title>
          <description>Time to event was calculated as date of onset of event — date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421.0" lower_limit="413.0">95% confidence interval upper limit not estimated.</measurement>
                    <measurement group_id="O2" value="NA">Parameters not estimated-data did not reach the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0270</p_value>
            <p_value_desc>Level of significance: 5% 2-sided</p_value_desc>
            <method>Wei-Lin-Weissfeld Method</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.790</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0842</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.641</ci_lower_limit>
            <ci_upper_limit>0.974</ci_upper_limit>
            <estimate_desc>A hazard ratio of &lt;1 represents a favourable outcome for the test treatment</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Third Moderate or Severe COPD Exacerbation</title>
        <description>Time to event was calculated as date of onset of event — date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.</description>
        <time_frame>52 Weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Third Moderate or Severe COPD Exacerbation</title>
          <description>Time to event was calculated as date of onset of event — date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Parameters not estimated-data did not reach the median.</measurement>
                    <measurement group_id="O2" value="NA">Parameters not estimated-data did not reach the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0731</p_value>
            <p_value_desc>Level of significance: 5% 2-sided</p_value_desc>
            <method>Wei-Lin-Weissfeld Method</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.749</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1209</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.546</ci_lower_limit>
            <ci_upper_limit>1.027</ci_upper_limit>
            <estimate_desc>A hazard ratio of &lt;1 represents a favourable outcome for the test treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Needed to Treat to Avoid 1 Moderate or Severe COPD Exacerbation Derived From Exacerbation Per Patient Per Year</title>
        <description>The number needed to treat (NNT) analysis is a simple, concise method to quantify directly the benefits that alternative treatment options have on disease outcomes in terms of the number of patients who need to be treated before a benefit is observed. Risk reduction: Rate(Placebo)— Rate (Roflumilast 500 μg), Number needed to treat for benefit (NNTB): 1/(Risk reduction). A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.</description>
        <time_frame>52 Weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Needed to Treat to Avoid 1 Moderate or Severe COPD Exacerbation Derived From Exacerbation Per Patient Per Year</title>
          <description>The number needed to treat (NNT) analysis is a simple, concise method to quantify directly the benefits that alternative treatment options have on disease outcomes in terms of the number of patients who need to be treated before a benefit is observed. Risk reduction: Rate(Placebo)— Rate (Roflumilast 500 μg), Number needed to treat for benefit (NNTB): 1/(Risk reduction). A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.805"/>
                    <measurement group_id="O2" value="0.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>NNTB</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4</ci_lower_limit>
            <ci_upper_limit>31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Moderate or Severe COPD Exacerbation Days</title>
        <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. The number of exacerbation days per patient is the sum of durations (stop date of exacerbation — start date of exacerbation + 1) of all exacerbations within the category.</description>
        <time_frame>52 Weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Moderate or Severe COPD Exacerbation Days</title>
          <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. The number of exacerbation days per patient is the sum of durations (stop date of exacerbation — start date of exacerbation + 1) of all exacerbations within the category.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" spread="23.09"/>
                    <measurement group_id="O2" value="30.9" spread="29.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Moderate or Severe COPD Exacerbations Per Participant</title>
        <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.</description>
        <time_frame>52 Weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis. n in each of the categories is the number of participants with exacerbations.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Moderate or Severe COPD Exacerbations Per Participant</title>
          <description>A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient’s baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis. n in each of the categories is the number of participants with exacerbations.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="10.59"/>
                    <measurement group_id="O2" value="16.6" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Post-Bronchodilator Forced Vital Capacity (FVC)</title>
        <description>Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.</description>
        <time_frame>52 weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-Bronchodilator Forced Vital Capacity (FVC)</title>
          <description>Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="928"/>
                <count group_id="O2" value="941"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.0114"/>
                    <measurement group_id="O2" value="-0.057" spread="0.0111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Level of significance: 5% 2-sided.</p_value_desc>
            <method>Repeated measurement model</method>
            <method_desc>Unstructured covariance structure and restricted maximum likelihood (REML).</method_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.092</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0159</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.061</ci_lower_limit>
            <ci_upper_limit>0.124</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Post-Bronchodilator Forced Expiratory Flow at 25% to 75% of Vital Capacity (FEF25-75%)</title>
        <description>Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.</description>
        <time_frame>52 weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-Bronchodilator Forced Expiratory Flow at 25% to 75% of Vital Capacity (FEF25-75%)</title>
          <description>Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>liters/second</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="928"/>
                <count group_id="O2" value="941"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" spread="0.0044"/>
                    <measurement group_id="O2" value="0.009" spread="0.0043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Level of significance: 5% 2-sided.</p_value_desc>
            <method>Repeated measurement model</method>
            <method_desc>Unstructured covariance structure and REML.</method_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.025</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0062</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.013</ci_lower_limit>
            <ci_upper_limit>0.038</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First 6 Seconds (FEV6)</title>
        <description>FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first six seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.</description>
        <time_frame>52 weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First 6 Seconds (FEV6)</title>
          <description>FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first six seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="924"/>
                <count group_id="O2" value="937"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.061" spread="0.0093"/>
                    <measurement group_id="O2" value="-0.033" spread="0.0091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Level of significance: 5% 2-sided.</p_value_desc>
            <method>Repeated measurement model</method>
            <method_desc>Unstructured covariance structure and REML.</method_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.094</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0131</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.069</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Post-Bronchodilator FEV1/FVC</title>
        <description>The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.</description>
        <time_frame>52 weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-Bronchodilator FEV1/FVC</title>
          <description>The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.170" spread="7.0339"/>
                    <measurement group_id="O2" value="0.580" spread="6.8405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Use of Rescue Medication From Daily Diary</title>
        <description>Salbutamol metered dose inhaler was available as rescue medication during the study. The participant recorded the use of rescue medication in a daily diary. A negative change from Baseline indicates an improvement.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data included in the repeated measurements analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Use of Rescue Medication From Daily Diary</title>
          <description>Salbutamol metered dose inhaler was available as rescue medication during the study. The participant recorded the use of rescue medication in a daily diary. A negative change from Baseline indicates an improvement.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data included in the repeated measurements analysis.</population>
          <units>puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="848"/>
                <count group_id="O2" value="896"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.109" spread="0.0676"/>
                    <measurement group_id="O2" value="0.173" spread="0.0654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <p_value_desc>Level of significance: 5% 2-sided.</p_value_desc>
            <method>Repeated measurement model</method>
            <method_desc>Compound symmetry covariance structure and REML.</method_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.283</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0941</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.467</ci_lower_limit>
            <ci_upper_limit>-0.098</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in COPD Symptom Score From Daily Diary</title>
        <description>Participants recorded COPD symptoms cough and sputum production in a daily diary. Cough was assessed using a 4-point scale where 0=No cough to 3=severe cough and sputum was assessed using a 4-point scale where 0=no sputum production to 3=severe sputum production. Least-squares means from ANCOVA including treatment by time interaction. A negative change from Baseline indicates improvement. Total symptom score is the sum of cough and sputum scores, ranging from 0 (best possible outcome) to 6 (worst possible outcome).</description>
        <time_frame>52 weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in COPD Symptom Score From Daily Diary</title>
          <description>Participants recorded COPD symptoms cough and sputum production in a daily diary. Cough was assessed using a 4-point scale where 0=No cough to 3=severe cough and sputum was assessed using a 4-point scale where 0=no sputum production to 3=severe sputum production. Least-squares means from ANCOVA including treatment by time interaction. A negative change from Baseline indicates improvement. Total symptom score is the sum of cough and sputum scores, ranging from 0 (best possible outcome) to 6 (worst possible outcome).</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="897"/>
                <count group_id="O2" value="932"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.412" spread="0.0315"/>
                    <measurement group_id="O2" value="-0.398" spread="0.0306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7392</p_value>
            <p_value_desc>Level of significance: 5% 2-sided.</p_value_desc>
            <method>Repeated measurement model</method>
            <method_desc>Compound symmetry covariance structure and REML.</method_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.015</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0439</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.101</ci_lower_limit>
            <ci_upper_limit>0.071</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Symptom-Free Days</title>
        <description>Symptoms of COPD (cough, sputum) were recorded in a daily diary. The percentage of days without symptoms is reported.</description>
        <time_frame>52 Weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Symptom-Free Days</title>
          <description>Symptoms of COPD (cough, sputum) were recorded in a daily diary. The percentage of days without symptoms is reported.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.09" spread="17.119"/>
                    <measurement group_id="O2" value="6.88" spread="16.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Rescue Medication-Free Days</title>
        <description>Participants recorded their use of rescue medication in a daily diary. The percentage of days without rescue medication use.</description>
        <time_frame>52 Weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Rescue Medication-Free Days</title>
          <description>Participants recorded their use of rescue medication in a daily diary. The percentage of days without rescue medication use.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.25" spread="33.734"/>
                    <measurement group_id="O2" value="22.77" spread="33.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in COPD Assessment Test (CAT) Total Score</title>
        <description>Participants completed the CAT questionnaire at Baseline and after 52 Weeks of Treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. A negative change from Baseline indicates improvement. Least-squares means from ANCOVA including treatment by time interaction.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in COPD Assessment Test (CAT) Total Score</title>
          <description>Participants completed the CAT questionnaire at Baseline and after 52 Weeks of Treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. A negative change from Baseline indicates improvement. Least-squares means from ANCOVA including treatment by time interaction.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="924"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.270" spread="0.1556"/>
                    <measurement group_id="O2" value="-0.985" spread="0.1518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1909</p_value>
            <p_value_desc>Level of significance: 5% 2-sided.</p_value_desc>
            <method>Repeated measurement model</method>
            <method_desc>Unstructured covariance structure and REML.</method_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.285</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2175</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.711</ci_lower_limit>
            <ci_upper_limit>0.142</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvement in CAT</title>
        <description>Participants completed the CAT questionnaire at Baseline and after 52 Weeks of treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. Improvement was defined as a CAT Total Score reduction from Baseline &gt; 1.6.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement in CAT</title>
          <description>Participants completed the CAT questionnaire at Baseline and after 52 Weeks of treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. Improvement was defined as a CAT Total Score reduction from Baseline &gt; 1.6.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2"/>
                    <measurement group_id="O2" value="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Mortality Due to Any Reason During the Treatment Period Score</title>
        <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
        <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Mortality Due to Any Reason During the Treatment Period Score</title>
          <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="44" upper_limit="381">Data did not reach the median.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="21" upper_limit="293">Data did not reach the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9414</p_value>
            <p_value_desc>Level of significance: 5% 2-sided.</p_value_desc>
            <method>Cox-proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.025</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3468</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.528</ci_lower_limit>
            <ci_upper_limit>1.990</ci_upper_limit>
            <estimate_desc>A hazards ratio of &lt; 1 represents a lower hazard for the test treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Mortality Due to COPD Exacerbation During the Treatment Period</title>
        <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
        <time_frame>52 Weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Mortality Due to COPD Exacerbation During the Treatment Period</title>
          <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="44" upper_limit="322">Data did not reach the median.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="25" upper_limit="293">Data did not reach the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8876</p_value>
            <method>Cox-proportional hazards model</method>
            <method_desc>Level of significance: 5% 2-sided.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.078</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5765</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.378</ci_lower_limit>
            <ci_upper_limit>3.075</ci_upper_limit>
            <estimate_desc>A hazards ratio of &lt; 1 represents a lower hazard for the test treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Withdrawal During the Treatment Period</title>
        <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
        <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Withdrawal During the Treatment Period</title>
          <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="420.0" lower_limit="5" upper_limit="428"/>
                    <measurement group_id="O2" value="444.0" lower_limit="1" upper_limit="444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cox-proportional hazards model</method>
            <method_desc>Level of significance: 5% 2-sided.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.529</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1463</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.268</ci_lower_limit>
            <ci_upper_limit>1.845</ci_upper_limit>
            <estimate_desc>A hazards ratio of &lt; 1 represents a lower hazard for the test treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Withdrawal Due to COPD Exacerbation During the Treatment Period</title>
        <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
        <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Withdrawal Due to COPD Exacerbation During the Treatment Period</title>
          <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="25" upper_limit="371">Data did not reach the median.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="12" upper_limit="319">Data did not reach the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3477</p_value>
            <p_value_desc>Level of significance: 5% 2-sided.</p_value_desc>
            <method>Cox-proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.695</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2691</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.326</ci_lower_limit>
            <ci_upper_limit>1.484</ci_upper_limit>
            <estimate_desc>A hazards ratio of &lt; 1 represents a lower hazard for the test treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Major Adverse Cardiovascular Event (MACE) During the Treatment Period</title>
        <description>Composite MACE is a combined endpoint (cardiovascular death [including death due to undetermined cause], nonfatal myocardial infarction, and nonfatal stroke).</description>
        <time_frame>52 Weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Major Adverse Cardiovascular Event (MACE) During the Treatment Period</title>
          <description>Composite MACE is a combined endpoint (cardiovascular death [including death due to undetermined cause], nonfatal myocardial infarction, and nonfatal stroke).</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Major Adverse Cardiovascular Event (MACE) During the Treatment Period</title>
        <description>Composite MACE is a combined endpoint(cardiovascular death [including death due to undetermined cause], nonfatal myocardial infarction, and nonfatal stroke). Time to event was calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
        <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Major Adverse Cardiovascular Event (MACE) During the Treatment Period</title>
          <description>Composite MACE is a combined endpoint(cardiovascular death [including death due to undetermined cause], nonfatal myocardial infarction, and nonfatal stroke). Time to event was calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="52" upper_limit="415">Data did not reach the median.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="50" upper_limit="365">Data did not reach the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8208</p_value>
            <p_value_desc>Level of significance: 5% 2-sided.</p_value_desc>
            <method>Cox-proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.083</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3832</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.542</ci_lower_limit>
            <ci_upper_limit>2.167</ci_upper_limit>
            <estimate_desc>A hazards ratio of &lt; 1 represents a lower hazard for the test treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participant With All-Cause Hospitalisation During the Treatment Period</title>
        <description>Percentage of patients with at least one hospital admission due to any cause.</description>
        <time_frame>52 Weeks</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participant With All-Cause Hospitalisation During the Treatment Period</title>
          <description>Percentage of patients with at least one hospital admission due to any cause.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9"/>
                    <measurement group_id="O2" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Hospitalisation Due to Any Cause During the Treatment Period</title>
        <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
        <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with events.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Hospitalisation Due to Any Cause During the Treatment Period</title>
          <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with events.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400.0" lower_limit="387.0" upper_limit="415.0"/>
                    <measurement group_id="O2" value="408.0" lower_limit="391.0" upper_limit="420.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7943</p_value>
            <p_value_desc>Level of significance: 5% 2-sided.</p_value_desc>
            <method>Cox-proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.977</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0865</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.821</ci_lower_limit>
            <ci_upper_limit>1.162</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Trial Withdrawal Due to an Adverse Event</title>
        <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
        <time_frame>52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)</time_frame>
        <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with events.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Trial Withdrawal Due to an Adverse Event</title>
          <description>Time to event will be calculated as date of onset of event — date of first intake of double-blind study drug + 1 day.</description>
          <population>Participants from the Intent-to treat population, all randomized participants who received at least 1 dose of study drug analyzed by the treatment for which they were randomized, with events.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="7" upper_limit="420">Data did not reach the median.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="13" upper_limit="444">Data did not reach the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced at Least 1 Treatment Emergent Adverse Event (TEAE)</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
        <time_frame>52 Weeks</time_frame>
        <population>Safety Population included all randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced at Least 1 Treatment Emergent Adverse Event (TEAE)</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
          <population>Safety Population included all randomized participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="968"/>
                <count group_id="O2" value="967"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9"/>
                    <measurement group_id="O2" value="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight</title>
        <description>Least Square Means was from an ANCOVA model including Last Observation Carried Forward (LOCF).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Participants from the Safety Population, all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight</title>
          <description>Least Square Means was from an ANCOVA model including Last Observation Carried Forward (LOCF).</description>
          <population>Participants from the Safety Population, all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>kilogram (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="938"/>
                <count group_id="O2" value="944"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.66" spread="0.130"/>
                    <measurement group_id="O2" value="-0.14" spread="0.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Mass Index (BMI)</title>
        <description>Body mass index (BMI) is a measure of body fat based on height and weight. Least Square Means was from an ANCOVA model including LOCF.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Participants from the Safety Population, all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 µg</title>
            <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Mass Index (BMI)</title>
          <description>Body mass index (BMI) is a measure of body fat based on height and weight. Least Square Means was from an ANCOVA model including LOCF.</description>
          <population>Participants from the Safety Population, all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>kg/m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="938"/>
                <count group_id="O2" value="944"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="0.046"/>
                    <measurement group_id="O2" value="-0.04" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <desc>Safety Population included all randomized participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Roflumilast 500 µg</title>
          <description>Roflumilast 500 µg tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo-matching roflumilast tablet, orally, once daily for 52 weeks. Background therapy concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="249" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="285" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Accessory auricle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Vitello-intestinal duct remnant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyrotoxic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Parotid abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Pneumonia moraxella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Urinary tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Transplant evaluation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Bladder adenocarcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Eyelid tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Trigeminal nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Psychotic disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="184" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Nasal septum disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Henoch-Schonlein purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Perivascular dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Alcohol detoxification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Aortic occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="967"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="968"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="967"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca Clinical Study Information Center</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

